ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
1,2,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
3,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
3,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
3,3,Headache,Headaches NEC,Headaches,Nerv,N
3,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
3,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
3,6,Vertigo,Inner ear signs and symptoms,Inner ear and VIIIth cranial nerve disorders,Ear,N
4,1,Neoplasm malignant,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
5,1,Diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
6,1,Catheter site thrombosis,Implant and catheter site reactions,Administration site reactions,Genrl,N
7,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
8,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
9,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
10,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
11,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
11,2,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
12,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
13,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
14,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
15,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
16,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
17,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
18,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
19,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
20,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
21,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
22,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
22,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
23,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
23,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
24,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
24,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
25,1,Injection site haemorrhage,Injection site reactions,Administration site reactions,Genrl,N
25,2,Product packaging issue,Product packaging issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
26,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
27,1,Retinal vein thrombosis,Retinal bleeding and vascular disorders (excl retinopathy),"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
28,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
29,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
30,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
31,1,Peripheral vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
32,1,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
33,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
33,2,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
34,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
34,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
35,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
35,2,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
35,3,Surgery,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
36,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
37,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
38,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
39,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
40,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
41,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
42,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
43,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
44,1,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
